Thrombus imaging using technetium-99m-labeled high-potency GPIIb/IIIa receptor antagonists. Chemistry and initial...

Area of Science:

• Biochemistry
• Radiochemistry
• Pharmacology

Background:

• Platelet-specific compounds labeled with gamma-emitting radionuclides are valuable for noninvasive in vivo thrombus detection.
• Development of targeted imaging agents requires potent inhibitors of platelet aggregation with radionuclide chelators.

Purpose of the Study:

• To synthesize novel peptides that inhibit platelet aggregation and chelate technetium-99m for thrombus imaging.
• To design stable oxotechnetium(V) species with well-defined metal coordination sites.
• To enhance binding affinities through structural modifications and oligomerization.

Main Methods:

• Peptide synthesis involving cyclization via S-alkylation of cysteine with a chloroacetyl group.
• Incorporation of Arg-Gly-Asp (RGD) pharmacophore or mimetics for receptor binding.
• Radiolabeling with technetium-99m and assessment in a canine thrombosis model.

Main Results:

• Peptides with constrained RGD mimetics demonstrated enhanced binding affinities.
• The most potent compounds inhibited human platelet aggregation with IC50s of approximately 0.03 microM.
• Technetium-99m labeled peptides (P280 and P748) showed potential in a canine thrombosis model.

Conclusions:

• The synthesized technetium-99m labeled peptides exhibit high receptor binding affinity and favorable characteristics for thrombus imaging.
• These compounds hold promise as effective agents for noninvasive in vivo detection of thrombi.
• Ease of preparation and expected rapid pharmacokinetics further support their potential clinical utility.